# ZS Pharma

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/zs-pharma

- Industry: Pharmaceuticals
- Headquarters: Coppell, US
- Website: www.zspharma.com
- Total disclosed funding: $46M
- Latest round: Series C (Oct 26, 2012)
- Investors on record: 6

## About

ZS Pharma, Inc. is a biopharmaceutical company that specializes in developing innovative treatments for patients with serious diseases, focusing on renal health and metabolic disorders.Founded in 2008, ZS Pharma, Inc. is based in Coppell, US, and focuses on the development of therapies for patients with kidney-related conditions. The company has a history of 14 deals, with its most recent funding round being a VENTURE DEBT of USD 20.00 mn raised from MidCap Financial on June 17, 2014. To date, ZS Pharma has raised a total of USD 106.00 mn. The company does not have known subsidiaries or parent company affiliations.ZS Pharma develops advanced pharmaceutical products aiming to address serious medical needs, particularly in renal and metabolic health. Their innovative treatment offerings are designed to improve patient outcomes and are targeted at healthcare providers and institutions across various geographic regions, including North America and Europe.In the most recent fiscal year, ZS Pharma reported an EBITDA of USD -58.848 mn. Revenue is generated through the sales of its prescription medications, which are distributed to healthcare providers and hospitals, supported by strategic partnerships with wholesalers and retailers.Following its recent funding round on June 17, 2014, ZS Pharma plans to utilize the raised capital to further the development of new products tailored for renal health and to expand its market presence in North America and Europe. The company is focused on bringing innovative therapies to market, with specific product launches expected in the coming years based on ongoing research and development initiatives.

## Funding rounds

- Series C, Oct 26, 2012, $46M — Alta Partners, RiverVest Ventures Partners, Devon Park Bioventures, Salem Partners, Partisan Management Group, 503 Partners
- Series A, Jul 3, 2012 — Devon Park Bioventures
- Series A, Dec 8, 2011 — Devon Park Bioventures
- Series A, Nov 10, 2011 — Devon Park Bioventures

## Investors

- Devon Park Bioventures (https://capitalatlas.ai/funds/devon-park-bioventures) — Series A, Series C
- Alta Partners (https://capitalatlas.ai/funds/alta-partners) — Series C
- RiverVest Ventures Partners (https://capitalatlas.ai/funds/rivervest-ventures-partners) — Series C
- Salem Partners — Series C
- Partisan Management Group (https://capitalatlas.ai/funds/partisan-management-group) — Series C
- 503 Partners (https://capitalatlas.ai/funds/503-partners) — Series C